Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 26/05/2021
• Auteurs : Clémence MercierMathieu PiocheEliane AlbuissonThierry PonchonJean-Michel GonzalèsMarc BarthetIsabelle BoytchevGeoffroy VanbiervlietClement Fortier BeaulieuFrederic PratArthur BelleJulien BranchePhilippe GrandvalJean-Christophe ValatsFranz RudlerTimothée WallenhorstStephane KochAurélie ComteNicolas WillietNicolas MusquerEmmanuel CoronAline DerosièreJean-Philippe Le MouelMarion SchaeferCaroline ChabotIsabelle ScheersPierre DeprezJean-Baptiste Chevaux
• Organismes : Centre Hospitalier Régional Universitaire de Nancy Laboratoire des applications thérapeutiques des ultrasons / Application des ultrasons à la thérapie Hôpital Edouard Herriot [CHU - HCL] Centre Hospitalier Régional Universitaire de Nancy Hôpital Edouard Herriot [CHU - HCL] Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille] Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille] Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre] Centre Hospitalier Universitaire de Nice Centre Hospitalier Universitaire de Nice Hôpital Cochin [AP-HP] Service de Gastro-entérologie [CHU Cochin] Hôpital Cochin [AP-HP] Service de Gastro-entérologie [CHU Cochin] Hôpital Claude Huriez [Lille] Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille] Centre de Recherche en Cancérologie de Marseille Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Hôpital Sud [CHU Rennes] Centre Hospitalier Régional Universitaire de Besançon Service de chirurgie pédiatrique [CHU Besançon] Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Service d'Hépato Gastroenterologie [CHU Amiens-Picardie] Service d'Hépato Gastroenterologie [CHU Amiens-Picardie] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Cliniques Universitaires Saint-Luc [Bruxelles] Cliniques Universitaires Saint-Luc [Bruxelles] Centre Hospitalier Régional Universitaire de Nancy
• Publié dans Endoscopy le 22/10/2020

---

Résumé : Introduction The aims of this retrospective multicenter study were to assess the technical success and adverse events of endoscopic retrograde cholangiopancreatography (ERCP) procedures in children in French and Belgian centers. Methods All children aged 1 day to 17 years who underwent ERCP between January 2008 and March 2019 in 15 tertiary care hospitals were retrospectively included. Results 271 children underwent 470 ERCP procedures. Clinical long-term follow-up was available for 72 % of our patients (340/470 procedures). The median age at intervention was 10.9 years. ERCP was therapeutic in 90 % (423/470) and diagnostic in cases of neonatal cholestasis in 10 % of the patients. The most common biliary indication was choledocholithiasis; the most common pancreatic indication was chronic pancreatitis. Biliary cannulation was successful in 92 % of cases (270/294); pancreatic cannulation in 96 % of cases (169/176); and planned therapeutic procedures in 92 % of cases (388/423). The overall complication rate was 19 % (65/340). The most common complication was post-ERCP pancreatitis (PEP) in 12 % of cases (40/340) and sepsis in 5 % (18/340). On univariate analyses, pancreatic stent removal was protective against PEP (odds ratio [OR] 0.1, 95 % confidence interval [CI] 0.01 – 0.75; P = 0.03), and sepsis was associated with history of liver transplantation (OR 7.27, 95 %CI 1.7 – 31.05; P = 0.01). Five patients had post-ERCP hemorrhage and two had intestinal perforation. All complications were managed with supportive medical care. There was no procedure-related mortality. Conclusion Our cohort demonstrates that ERCP can be performed safely with high success rates in many pancreaticobiliary diseases of children. The rate of adverse events was similar to that in previous reports.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 26/05/2021
• Auteurs : Lorenzo MugnaiDarius Modirrousta-GalianBilly EdwardsQuentin ChangeatJeroen BouwmanGiuseppe MorelloAhmed Al-RefaieRobin BaeyensMichelle Fabienne BiegerDoriann BlainAmélie GressierGloria GuilluyYassin JaziriFlavien KieferMario MorvanWilliam PlurielMathilde PovedaNour SkafNiall WhitefordSam WrightKai Hou YipTiziano ZingalesBenjamin CharnayPierre DrossartJérémy LeconteOlivia VenotIngo WaldmannJean-Philippe Beaulieu
• Organismes : Dipartimento di Fisica [Roma La Sapienza] INAF - Osservatorio Astronomico di Palermo Dipartimento di Fisica e Chimica [Palermo] Department of Physics and Astronomy [UCL London] Department of Physics and Astronomy [UCL London] Max-Planck-Institut für Astronomie INAF - Osservatorio Astronomico di Palermo Instituto de Astrofisica de Canarias Department of Physics and Astronomy [UCL London] Institute of Astronomy [Leuven] College of Engineering, Mathematics and Physical Sciences [Exeter] Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut d'Astrophysique de Paris Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics PLANETO - LATMOS Dipartimento di Fisica [Torino] INAF - Osservatorio Astrofisico di Torino Laboratoire d'Astrophysique de Bordeaux [Pessac] Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Department of Physics and Astronomy [UCL London] Laboratoire d'Astrophysique de Bordeaux [Pessac] Laboratoire Interuniversitaire des Systèmes Atmosphériques Maison de la Simulation Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Subaru Telescope Department of Physics and Astronomy [UCL London] Institute for Astronomy [Edinburgh] Centre for Exoplanet Science Department of Physics and Astronomy [UCL London] Department of Physics and Astronomy [UCL London] Laboratoire d'Astrophysique de Bordeaux [Pessac] Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Institut d'Astrophysique de Paris Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Laboratoire d'Astrophysique de Bordeaux [Pessac] Laboratoire Interuniversitaire des Systèmes Atmosphériques University College London [UCL] Institut d'Astrophysique de Paris School of Physical Sciences [Hobart]
• Publié dans The Astronomical Journal le 22/10/2020

---

Résumé : We present a study on the spatially scanned spectroscopic observations of the transit of GJ 1132 b, a warm (∼500 K) super-Earth (1.13 R⊕) that was obtained with the G141 grism (1.125–1.650 μm) of the Wide Field Camera 3 (WFC3) on board the Hubble Space Telescope. We used the publicly available Iraclis pipeline to extract the planetary transmission spectra from the five visits and produced a precise transmission spectrum. We analyzed the spectrum using the TauREx3 atmospheric retrieval code, with which we show that the measurements do not contain molecular signatures in the investigated wavelength range and are best fit with a flat-line model. Our results suggest that the planet does not have a clear primordial, hydrogen-dominated atmosphere. Instead, GJ 1132 b could have a cloudy hydrogen-dominated atmosphere, have a very enriched secondary atmosphere, be airless, or have a tenuous atmosphere that has not been detected. Due to the narrow wavelength coverage of WFC3, these scenarios cannot be distinguished yet, but the James Webb Space Telescope may be capable of detecting atmospheric features, although several observations may be required to provide useful constraints.

---

Fichiers liés : 2104.01873.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 25/05/2021
• Auteurs : Antoine RoquillyJean Denis MoyerOlivier HuetSigismond LasockiBenjamin CohenClaire Dahyot-FizelierKevin ChalardPhilippe SeguinCaroline JeantrelleVéronique VermeerschThomas GaillardRaphael CinottiDominique Demeure Dit LattePierre Joachim MaheMickael Vourc’hFlorian Pierre MartinAlice ChopinCéline LerebourgLaurent FletAnne ChiffoleauFanny FeuilletKarim Asehnoune
• Organismes : Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital Beaujon [AP-HP] CHRU Brest - Département d'Anesthésie Réanimation Optimisation des régulations physiologiques Centre Hospitalier Universitaire d'Angers CHU Trousseau [Tours] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Pharmacologie des anti-infectieux [U 1070] Université de Poitiers – UFR Santé [Faculté de Médecine et de Pharmacie] CHU Montpellier = Montpellier University Hospital Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Hôpital Beaujon [AP-HP] CHRU Brest - Département d'Anesthésie Réanimation Centre Hospitalier Universitaire d'Angers Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital methodS in Patients-centered outcomes and HEalth ResEarch Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
• Publié dans JAMA Cardiology le 25/10/2020

---

Résumé : Importance: Fluid therapy is an important component of care for patients with traumatic brain injury, but whether it modulates clinical outcomes remains unclear.Objective: To determine whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury.Design, setting, and participants: Multicenter randomized clinical trial conducted in 9 intensive care units in France, including 370 patients with moderate to severe traumatic brain injury who were recruited from October 2017 to August 2019. Follow-up was completed in February 2020.Interventions: Adult patients with moderate to severe traumatic brain injury were randomly assigned to receive continuous infusion of 20% hypertonic saline solution plus standard care (n = 185) or standard care alone (controls; n = 185). The 20% hypertonic saline solution was administered for 48 hours or longer if patients remained at risk of intracranial hypertension.Main outcomes and measures: The primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lower scores indicating worse functional outcome) at 6 months, obtained centrally by blinded assessors and analyzed with ordinal logistic regression adjusted for prespecified prognostic factors (with a common odds ratio [OR] >1.0 favoring intervention). There were 12 secondary outcomes measured at multiple time points, including development of intracranial hypertension and 6-month mortality.Results: Among 370 patients who were randomized (median age, 44 [interquartile range, 27-59] years; 77 [20.2%] women), 359 (97%) completed the trial. The adjusted common OR for the GOS-E score at 6 months was 1.02 (95% CI, 0.71-1.47; P = .92). Of the 12 secondary outcomes, 10 were not significantly different. Intracranial hypertension developed in 62 (33.7%) patients in the intervention group and 66 (36.3%) patients in the control group (absolute difference, -2.6% [95% CI, -12.3% to 7.2%]; OR, 0.80 [95% CI, 0.51-1.26]). There was no significant difference in 6-month mortality (29 [15.9%] in the intervention group vs 37 [20.8%] in the control group; absolute difference, -4.9% [95% CI, -12.8% to 3.1%]; hazard ratio, 0.79 [95% CI, 0.48-1.28]).Conclusions and relevance: Among patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. However, confidence intervals for the findings were wide, and the study may have had limited power to detect a clinically important difference.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 21/05/2021
• Auteurs : Sophie GarnierMagdalena HarakalovaStefan WeissMichal MokryVera Regitz-ZagrosekChristian HengstenbergThomas CappolaRichard IsnardEloisa ArbustiniStuart CookJessica van SettenJorg CalisHakon HakonarsonMichael MorleyKlaus StarkSanjay PrasadJin LiDeclan O'ReganMaurizia GrassoMartina Müller-NurasyidThomas MeitingerJean‐philippe EmpanaKonstantin StrauchMelanie WaldenbergerKenneth MarguilesChristine SeidmanGeorgios KararigasBenjamin MederJan HaasPierre BoutouyriePatrick LacolleyXavier JouvenJeanette ErdmannStefan BlankenbergThomas WichterVolker RuppertLuigi TavazziOlivier DubourgGérard RoizesRichard DorentPascal de GrooteLaurent FauchierJean-Noël TrochuJean-François AupetitZofia BilinskaMarine GermainUwe VölkerDaiane HemerichIbticem RajiDelphine Bacq-DaianCarole ProustPaloma RemiorManuel Gomez-BuenoKristin LehnertRenee MaasRobert OlasoGanapathi Varma SaripellaStephan FelixSteven McginnLaëtitia Duboscq-BidotAlain van MilCéline BesseVincent FontaineHélène BlanchéFlavie AderBrendan KeatingAngélique CurjolAnne BolandMichel KomajdaFrançois CambienJean‐françois DeleuzeMarcus DörrFolkert W AsselbergsEric VillardDavid-Alexandre TrégouëtPhilippe Charron
• Organismes : Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases University Medical Center [Utrecht] Universität Greifswald = University of Greifswald German Center for Cardiovascular Research University Medical Center [Utrecht] Charité - UniversitätsMedizin = Berlin University Medicine German Center for Cardiovascular Research University of Pennsylvania [Philadelphia] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Istituti di Ricovero e Cura a Carattere Scientifico National Heart Centre Singapore University Medical Center [Utrecht] University Medical Center [Utrecht] Children’s Hospital of Philadelphia University of Pennsylvania [Philadelphia] Universität Regensburg = University of Regensburg = Université de Ratisbonne [Allemagne] Royal Brompton Hospital [London, United Kingdom] Children’s Hospital of Philadelphia Imperial College London Istituti Clinici Scientifici Maugeri [Pavia] Helmholtz Zentrum München = German Research Center for Environmental Health Helmholtz Zentrum München = German Research Center for Environmental Health Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München Technische Universität Munchen = Technical University Munich = Université Technique de Munich Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Helmholtz Zentrum München = German Research Center for Environmental Health Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München Universitätsmedizin der Johannes Gutenberg-Universität Mainz - University Medical Center of the Johannes Gutenberg-University Mainz [Germany] Helmholtz Zentrum München = German Research Center for Environmental Health German Center for Cardiovascular Research Perelman School of Medicine Harvard Medical School [Boston] University of Iceland [Reykjavik] Universität Heidelberg [Heidelberg] = Heidelberg University Stanford University Universität Heidelberg [Heidelberg] = Heidelberg University Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Hôpital Européen Georges Pompidou [APHP] Défaillance Cardiovasculaire Aiguë et Chronique Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Hôpital Européen Georges Pompidou [APHP] Universitätsmedizin der Johannes Gutenberg-Universität Mainz - University Medical Center of the Johannes Gutenberg-University Mainz [Germany] Universität zu Lübeck = University of Lübeck [Lübeck] Universitätklinikum Gießen und Marburg GmbH Universitätklinikum Gießen und Marburg GmbH Maria Cecilia Hospital Université de Versailles Saint-Quentin-en-Yvelines Institut de génétique humaine CHU Tenon [AP-HP] Hôpital cardiologique CHU Trousseau [Tours] ITX - unité de recherche de l'institut du thorax Centre hospitalier Saint Joseph - Saint Luc [Lyon] National Institute of Cardiology [Varsovie, Pologne] Bordeaux population health University of Medicine Greifswald German Center for Cardiovascular Research University Medical Center [Utrecht] Centre de Référence Maladies Cardiaques Héréditaires Centre National de Recherche en Génomique Humaine Laboratoire d'excellence en GENomique MEDicale Bordeaux population health Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain] Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain] Universität Greifswald = University of Greifswald German Center for Cardiovascular Research University Medical Center [Utrecht] Centre National de Recherche en Génomique Humaine Laboratoire d'excellence en GENomique MEDicale Swedish University of Agricultural Sciences = Sveriges lantbruksuniversitet Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases German Center for Cardiovascular Research Universität Greifswald = University of Greifswald Centre National de Recherche en Génomique Humaine Laboratoire d'excellence en GENomique MEDicale Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases University Medical Center [Utrecht] Centre National de Recherche en Génomique Humaine Laboratoire d'excellence en GENomique MEDicale Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Centre d'Etude du Polymorphisme Humain Laboratoire d'excellence en GENomique MEDicale Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases CHU Pitié-Salpêtrière [AP-HP] Faculté de Pharmacie de Paris - Université Paris Descartes University of Pennsylvania [Philadelphia] Centre de Référence Maladies Cardiaques Héréditaires Centre National de Recherche en Génomique Humaine Laboratoire d'excellence en GENomique MEDicale Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Hospitalier Paris Saint-Joseph Bordeaux population health Centre National de Recherche en Génomique Humaine Fondation Jean Dausset - Centre d’Etudes du Polymorphisme Humain [Paris] Laboratoire d'excellence en GENomique MEDicale German Center for Cardiovascular Research Universität Greifswald = University of Greifswald University Medical Center [Utrecht] University College London [UCL] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Bordeaux population health Laboratoire d'excellence en GENomique MEDicale Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases CHU Pitié-Salpêtrière [AP-HP] Centre de Référence Maladies Cardiaques Héréditaires
• Publié dans European Heart Journal le 30/10/2020

---

Résumé : Abstract Aims Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. Methods and results We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P = 8.7 × 10−11 and 7.7 × 10−4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P = 3.3 × 10−8 and 1.4 × 10−3 in the discovery and replication steps, respectively), while confirming two previously identified DCM loci on chromosomes 10 and 1, BAG3 and HSPB7. A genetic risk score constructed from the number of risk alleles at these four DCM loci revealed a 3-fold increased risk of DCM for individuals with 8 risk alleles compared to individuals with 5 risk alleles (median of the referral population). In silico annotation and functional 4C-sequencing analyses on iPSC-derived cardiomyocytes identify SLC6A6 as the most likely DCM gene at the 3p25.1 locus. This gene encodes a taurine transporter whose involvement in myocardial dysfunction and DCM is supported by numerous observations in humans and animals. At the 22q11.23 locus, in silico and data mining annotations, and to a lesser extent functional analysis, strongly suggest SMARCB1 as the candidate culprit gene. Conclusion This study provides a better understanding of the genetic architecture of DCM and sheds light on novel biological pathways underlying heart failure.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/05/2021
• Auteurs : Nuria KoteckiMaria Alice B FranzoiMarianne PaesmansFlorian ClatotEdith BorcomanAnthony GonçalvesPhilippe BarthelemyClaire CheymolJean-Pierre DelordAndrea GombosVincent VanhaudenardeStephane HolbrechtsFrancois DuhouxJean-Luc Re CanonLore DecosterHannelore DenysCaroline DuhemNadège KindtAhmad Awada
• Organismes : Centre de Recherche en Cancérologie de Marseille
• Publié dans Journal of Clinical Oncology le 01/11/2020

---

Résumé : TPS2066 Background: Better knowledge on the evolving epidemiology and biology of CNS metastases are key elements for the development of new treatment strategies and identification of promising therapeutic targets. A multidisciplinary Brain Metastases Clinical Research Platform called BrainStorm was launched by the Jules Bordet Institute and the Oncodistinct network. The BrainStorm program includes mainly patients with non-CNS metastatic solid tumors with high risk of developing CNS metastases allowing to build a large database focusing on three time periods: before the diagnosis of CNS metastases (Part A), at diagnosis (Part B) and after the diagnosis of CNS metastases (Part C). Methods: Subjects with newly diagnosed non-CNS metastases or up to 24 months from diagnosis of non-CNS metastases from triple-negative and HER2-positive breast cancer, lung cancer and melanoma are eligible for part A of the program. Subjects presenting with a 1st CNS event and not yet enrolled (previously mentioned cohorts and a cohort of other tumor types) can enter directly in parts B and subsequently part C of the study. Eligible subjects are followed for 48 months for relevant clinical data, neurological examinations, quality of life, survival status, and undergo examinations and samplings (Table 1). A total of 280 subjects (40 per cohort) with a 1st CNS event will be enrolled. The main objectives of the program are to collect clinical and biological data with the aim to identify risk factors for CNS metastases development (Part A) and to better understand the biology of CNS metastases (brain and leptomeningeal –Parts B and C) aiming to discover new targets for therapy and intensify the multidisciplinary approach for the management of CNS metastases from solid tumors. The translational part of the program will evaluate among others the use of cerebrospinal fluid circulating tumor DNA (CSF-ctDNA) as a surrogate for CNS metastases in order to characterize its molecular landscape. Currently, the study is recruiting in several sites within the Oncodistinct network. The data collected will help to develop innovative multidisciplinary research projects that could be implemented in all parts of the BrainStorm program. Clinical trial information: NCT04109131. [Table: see text]

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 20/05/2021
• Auteurs : Jean-Luc MoriceauGéraldine GuérillotPierre-Antoine ChardelPhilippe Castelnau
• Organismes : Département Droit, Économie et Finances Laboratoire en Innovation, Technologies, Economie et Management (EA 7363) Umalis lab (ESCP Europe & Institut Mines-Télécom-Télécom Ecole de Management) Institut interdisciplinaire d'anthropologie du contemporain Laboratoire Sens et Compréhension du Monde Contemporain Département Droit, Économie et Finances Département Droit, Économie et Finances Laboratoire en Innovation, Technologies, Economie et Management (EA 7363)

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 17/05/2021
• Auteurs : Charlotte ArnaudMarion BoulangerAurélien LorthioirLaurence AmarArshid AzarineLouis BoyerGilles ChatellierSilvia Di MonacoXavier JeunemaitreAdrian KastlerElie MousseauxCatherine OppenheimFrédéric ThonyAlexandre PersuJeffrey W OlinAnne BlanchardEmmanuel TouzéAntoine ChedidBéatrice FiquetPierre‐françois PlouinJean‐philippe BaguetOlivier OrmezzanoFrançois SilholEric BodiguelValérie DomigoMarta PasquiniDenis TrystramPierre ClavelouBernard ChamontinBéatrice Duly‐bouhanickHilde HénonClaire Mounier‐vehierParla AstarciPierre GoffetteFrank HammerJean‐philippe LengeléFrancesca SeverinoRobert VerhelstClaire Le HelloPhilippe GosseDominique HervéFernando PicoMichèle KesslerPatrick RossignolYves SansonMathieu ZuberMikaël MazighiSonia Alamowitch
• Organismes : Physiopathologie et imagerie des troubles neurologiques CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Physiopathologie et imagerie des troubles neurologiques CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Service de radiologie cardio-vasculaire [CHU HEGP] CHU Gabriel Montpied [Clermont-Ferrand] Hôpital Européen Georges Pompidou [APHP] Department of Medical Sciences [Turin, Italy] Université Catholique de Louvain = Catholic University of Louvain Cliniques Universitaires Saint-Luc [Bruxelles] Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Universitaire [CHU Grenoble] Service de radiologie cardio-vasculaire [CHU HEGP] Institut de psychiatrie et neurosciences de Paris Service de neuroradiologie [Paris] Centre Hospitalier Universitaire [CHU Grenoble] Université Catholique de Louvain = Catholic University of Louvain Cliniques Universitaires Saint-Luc [Bruxelles] Icahn School of Medicine at Mount Sinai [New York] CIC - HEGP Physiopathologie et imagerie des troubles neurologiques CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Défaillance Cardiovasculaire Aiguë et Chronique Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] French-Clinical Research Infrastructure Network - F-CRIN [Paris]
• Publié dans Journal of the American Heart Association le 28/10/2020

---

Résumé : Background Cervical artery dissection (CeAD) is a frequent manifestation of fibromuscular dysplasia (FMD). However, risk factors for CeAD are unknown. We investigated factors associated with CeAD in the ARCADIA (Assessment of Renal and Cervical Artery Dysplasia) registry. Methods and Results The ARCADIA registry includes women or men aged ≥18 years, with a diagnosis of renal, cervical, or intracranial artery FMD, who were prospectively recruited at 16 university hospitals in France and Belgium. Diagnosis of acute or past CeAD at inclusion was established on imaging according to standard diagnostic criteria. Associations between potential determinants and CeAD were assessed by logistic regression analyses. Among 469 patients (75 men) with FMD, 65 (13.9%) had CeAD. Patients with CeAD were younger, more likely to be men, have a history of migraine, and less likely to have a history of hypertension than patients without CeAD. In the multivariable analysis, male sex (odds ratio [OR], 2.66; 95% CI, 1.34–5.25), history of migraine (OR, 1.90; 95% CI, 1.06–3.39), age ≥50 years (OR, 0.41; 95% CI, 0.23–0.73), history of hypertension (OR, 0.35; 95% CI, 0.20–0.64), and involvement of ≥3 vascular beds (OR, 2.49; 95% CI, 1.15–5.40) were significantly associated with CeAD. To validate the association between CeAD and sex, we performed a systematic review. We collected additional data on sex from 2 published studies and unpublished data from the US Registry for Fibromuscular Dysplasia and the European/International FMD Registry. In the pooled analysis (289 CeAD, 1933 patients), male sex was significantly associated with CeAD (OR, 2.04; 95% CI, 1.41–2.95; I 2 =0%). Conclusions In patients with FMD, male sex and multisite involvement are associated with CeAD, in addition to other previously known risk factors.

---

Fichiers liés : JAHA.120.018311.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/05/2021
• Auteurs : Jean ReignierAmélie Le GougeJean-Baptiste LascarrouDjillali AnnaneLaurent ArgaudYannick HourmantPierre AsfarJulio BadieMai-Anh NayNicolae-Vlad BotocLaurent BrisardHoang-Nam BuiDelphine ChatellierLouis ChauvelotAlain CombesChristophe CraccoMichaël DarmonVincent DasMatthieu DebarreAgathe DelboveJérôme DevaquetSebastian VoicuNadia Aissaoui-BalanantLouis-Marie DumontJohanna OzielOlivier GontierSamuel GroyerBertrand GuidetSamir JaberFabien LambiotteChristophe LeroyPhilippe LetocartBenjamin MadeuxJulien MaizelOlivier MartinetFrédéric MartinoEmmanuelle MercierJean-Paul MiraSaad NseirWalter PicardGaël PitonGaetan PlantefeveJean-Pierre QuenotAnne RenaultLaurent GuérinJack RichecoeurJean-Philippe RigaudFrancis SchneiderDaniel SilvaMichel SirodotBertrand SouweineFlorian ReizineFabienne TamionNicolas TerziDidier ThéveninGuillaume ThieryNathalie Thieulot-RolinJean-François TimsitFrançois TinturierPatrice TirotThierry VanderlindenIsabelle VinatierChristophe VinsonneauDiane MaugarsBruno Giraudeau
• Organismes : Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d’Investigation Clinique [Tours] CIC 1415 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Service médical des soins intensifs [CHU Raymond Poincaré] Cardiovasculaire, métabolisme, diabétologie et nutrition Hôpital Edouard Herriot [CHU - HCL] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire d'Angers Hôpital Nord Franche-Comté [Hôpital de Trévenans] Centre Hospitalier Regional d'Orléans CH de Saint-Malo [Broussais] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Service Anesthésie - Réanimation [Bordeaux] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Service d'anesthésie-réanimation [Centre Hospitalier Lyon Sud - HCL] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Centre Hospitalier d'Angoulême Service d'anesthésie-réanimation-CTB [CHU Saint Louis] Centre Hospitalier Intercommunal André Grégoire [Montreuil] Hôpital de Saint-Brieuc [Hôpital Yves Le Foll] Centre hospitalier Bretagne Atlantique (Morbihan) Hôpital Foch [Suresnes] Département d’Anesthésie-Réanimation-SMUR [Hôpital Lariboisière] Service d'Anesthésie-Réanimation [CHU HEGP] Service de Réanimation Médico-Chirurgicale [Hôpital Louis Mourier] Service d'anesthésie-réanimation [Avicenne] Service de Réanimation polyvalente [Chartres] Centre hospitalier de Montauban CHU Saint-Antoine [AP-HP] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier de Valenciennes Centre Hospitalier Emile Roux [Le Puy-en-Velay] Centre Hospitalier Rodez Centre Hospitalier de Bigorre [Tarbes] Médecine Intensive-Réanimation [CHU Amiens] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion] CHU Pointe-à-Pitre / Abymes [Guadeloupe] Centre Hospitalier Régional Universitaire de Tours Service de réanimation médicale polyvalente [CHU Cochin] Centre Hospitalier Régional Universitaire [CHU Lille] Centre hospitalier de Pau Service de Réanimation médicale [CHRU Besançon] Centre hospitalier Victor Dupouy [Centre hospitalier d'Argenteuil] Service de Réanimation Médicale (CHU de Dijon) CHRU Brest - Service de Réanimation Médicale Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Simone Veil de Beauvais [Beauvais] Service de réanimation polyvalente [Centre Hospitalier de Dieppe] Service de Médecine Intensive et Réanimation [Strasbourg] Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier d'Annecy Genevois Service Anésthésie et Réanimation [CHU Clermont-Ferrand] Service d'Anesthésie Réanimation [Rennes] Service de Réanimation Médicale [CHU Rouen] Service de Réanimation Médicale [Grenoble] Centre Hospitalier de Lens Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier de Melun Service d'anesthésie - réanimation chirurgicale [CHU Bichat] Médecine Intensive-Réanimation [CHU Amiens] Service Réanimation médico-chirurgicale [CH Le Mans] Groupement des Hôpitaux de l'Institut Catholique de Lille Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Centre Hospitalier de Béthune Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d’Investigation Clinique [Tours] CIC 1415
• Publié dans BMJ Open le 26/10/2020

---

Résumé : Introduction: International guidelines include early nutritional support (≤48 hour after admission), 20–25 kcal/kg/day, and 1.2–2 g/kg/day protein at the acute phase of critical illness. Recent data challenge the appropriateness of providing standard amounts of calories and protein during acute critical illness. Restricting calorie and protein intakes seemed beneficial, suggesting a role for metabolic pathways such as autophagy, a potential key mechanism in safeguarding cellular integrity, notably in the muscle, during critical illness. However, the optimal calorie and protein supply at the acute phase of severe critical illness remains unknown. NUTRIREA-3 will be the first trial to compare standard calorie and protein feeding complying with guidelines to low-calorie low-protein feeding. We hypothesised that nutritional support with calorie and protein restriction during acute critical illness decreased day 90 mortality and/or dependency on intensive care unit (ICU) management in mechanically ventilated patients receiving vasoactive amine therapy for shock, compared with standard calorie and protein targets. Methods and analysis: NUTRIREA-3 is a randomised, controlled, multicentre, open-label trial comparing two parallel groups of patients receiving invasive mechanical ventilation and vasoactive amine therapy for shock and given early nutritional support according to one of two strategies: early calorie-protein restriction (6 kcal/kg/day-0.2–0.4 g/kg/day) or standard calorie-protein targets (25 kcal/kg/day, 1.0–1.3 g/kg/day) at the acute phase defined as the first 7 days in the ICU. We will include 3044 patients in 61 French ICUs. Two primary end-points will be evaluated: day 90 mortality and time to ICU discharge readiness. The trial will be considered positive if significant between-group differences are found for one or both alternative primary endpoints. Secondary outcomes include hospital-acquired infections and nutritional, clinical and functional outcomes. Ethics and dissemination: The NUTRIREA-3 study has been approved by the appropriate ethics committee. Patients are included after informed consent. Results will be submitted for publication in peer-reviewed journals.

---

Fichiers liés : e045041.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/05/2021
• Auteurs : Chakali EswaraiahDi LiRay FuruyaTetsuo HasegawaDaniel R. van RossumKeping QiuNagayoshi OhashiKate PattleSarah SadavoyCharles HullDavid BerryYasuo DoiTao-Chung ChingShih-Ping LaiJia-Wei WangPatrick M KochJungmi KwonWoojin KwonPierre BastienDoris ArzoumanianSimon CoudéArchana SoamLapo FanciulloHsi-Wei YenJunhao LiuThiem HoangWen Ping ChenYoshito ShimajiriTie LiuZhiwei ChenHua-Bai LiA-Ran LyoJihye HwangDoug JohnstoneRamprasad RaoNguyen Bich NgocPham Ngoc DiepSteve MairsHarriet ParsonsMotohide TamuraMehrnoosh TahaniHuei-Ru Vivien ChenFumitaka NakamuraHiroko ShinnagaYa-Wen TangJungyeon ChoChang Won LeeShu-Ichiro InutsukaTsuyoshi InoueKazunari IwasakiLei QianJinjin XieDalei LiHong-Li LiuChuan-Peng ZhangMike ChenGuoyin ZhangLei ZhuJianjun ZhouPh. AndréSheng-Yuan LiuJinghua YuanXing LuNicolas PerettoTyler BourkeDo-Young ByunSophia DaiYan DuanHao-Yuan DuanDavid EdenBrenda MatthewsJason FiegeLaura FisselKee-Tae KimChin-Fei LeeJongsoo KimTae-Soo PyoYunhee ChoiMinho ChoiAntonio ChrysostomouEun Jung ChungLe Ngoc TramErica FranzmannPer FribergRachel FriesenGary FullerTim GledhillSarah GravesJane GreavesMatt GriffinQilao GuIlseung HanJennifer HatchellSaeko HayashiMartin HoudeKoji KawabataIl-Gyo JeongJi-Hyun KangSung-Ju KangMiju KangAkimasa KataokaFrancisca KemperMark RawlingsJonathan RawlingsBrendan RetterJohn RicherAndrew RigbyHiro SaitoGiorgio SaviniAnna ScaifeMasumichi SetaGwanjeong KimKyoung Hee KimMi-Ryang KimFlorian KirchschlagerJason KirkMasato KobayashiVera KonyvesTakayoshi KusuneKevin LacailleChi-Yan LawSang-Sung LeeYong-Hee LeeMasafumi MatsumuraGerald Moriarty-SchievenTetsuya NagataHiroyuki NakanishiTakashi OnakaGeumsook ParkXindi TangKohji TomisakaYusuke TsukamotoSerena VitiHongchi WangAnthony WhitworthHyunju YooHyeong-Sik YunTetsuya ZenkoYapeng ZhangIlse de LoozeC. Darren DowellStewart EyresSam FalleJean-François RobitailleSven van Loo
• Organismes : Laboratoire d'Astrophysique de Marseille Institut de Planétologie et d'Astrophysique de Grenoble
• Publié dans The Astrophysical Journal Letters le 28/10/2020

---

Résumé : Abstract We have obtained sensitive dust continuum polarization observations at 850 μ m in the B213 region of Taurus using POL-2 on SCUBA-2 at the James Clerk Maxwell Telescope as part of the B -fields in STar-forming Region Observations (BISTRO) survey. These observations allow us to probe magnetic field ( B -field) at high spatial resolution (∼2000 au or ∼0.01 pc at 140 pc) in two protostellar cores (K04166 and K04169) and one prestellar core (Miz-8b) that lie within the B213 filament. Using the Davis–Chandrasekhar–Fermi method, we estimate the B -field strengths in K04166, K04169, and Miz-8b to be 38 ± 14, 44 ± 16, and 12 ± 5 μ G, respectively. These cores show distinct mean B -field orientations. The B -field in K04166 is well ordered and aligned parallel to the orientations of the core minor axis, outflows, core rotation axis, and large-scale uniform B -field, in accordance with magnetically regulated star formation via ambipolar diffusion taking place in K04166. The B -field in K04169 is found to be ordered but oriented nearly perpendicular to the core minor axis and large-scale B -field and not well correlated with other axes. In contrast, Miz-8b exhibits a disordered B -field that shows no preferred alignment with the core minor axis or large-scale field. We found that only one core, K04166, retains a memory of the large-scale uniform B -field. The other two cores, K04169 and Miz-8b, are decoupled from the large-scale field. Such a complex B -field configuration could be caused by gas inflow onto the filament, even in the presence of a substantial magnetic flux.

---

Fichiers liés : Eswaraiah_2021_ApJL_912_L27.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/05/2021
• Auteurs : Geoffroy PouletFanny GarlanSonia GarrigouEleonora ZontaLeonor BenhaimMarie-Jennifer CarrillonAudrey DidelotDelphine Le CorreClaire MulotPhilippe NizardFrederic GinotAudrey Boutonnet-RodatHelene BlonsJean-Baptiste BachetJulien TaïebAziz ZaananVanna GeromelLaurence PellegrinaPierre Laurent-PuigShu-Fang Wang-RenaultValerie Taly
• Organismes : Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Institut Gustave Roussy Centre de Recherche des Cordeliers Département de chirurgie viscérale [Gustave Roussy] Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers Hôpital Européen Georges Pompidou [APHP] Centre de Recherche des Cordeliers Adelis Technologies Adelis Technologies Centre de Recherche des Cordeliers Service d'oncologie médicale [CHU HEGP] Centre de Recherche des Cordeliers CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche des Cordeliers Service d'oncologie médicale [CHU HEGP] Centre de Recherche des Cordeliers Service d'oncologie médicale [CHU HEGP] Eurofins Biomnis Eurofins Biomnis Centre de Recherche des Cordeliers Service d'oncologie médicale [CHU HEGP] Centre de Recherche des Cordeliers Centre de Recherche des Cordeliers
• Publié dans Frontiers in Oncology le 26/10/2020

---

Résumé : Background: Cellular-cell free-DNA (ccfDNA) is being explored as a diagnostic and prognostic tool for various diseases including cancer. Beyond the evaluation of the ccfDNA mutational status, its fragmentation has been investigated as a potential cancer biomarker in several studies. However, probably due to a lack of standardized procedures dedicated to preanalytical and analytical processing of plasma samples, contradictory results have been published. Methods: ddPCR assays allowing the detection of KRAS wild-type and mutated sequences ( KRAS p.G12V, pG12D, and pG13D) were designed to target different fragments sizes. Once validated on fragmented and non-fragmented DNA extracted from cancer cell lines, these assays were used to investigate the influence of the extraction methods on the non-mutated and mutated ccfDNA integrity reflected by the DNA integrity index (DII). The DII was then analyzed in two prospective cohorts of metastatic colorectal cancer patients (RASANC study n = 34; PLACOL study n = 12) and healthy subjects ( n = 49). Results and Discussion: Our results demonstrate that ccfDNA is highly fragmented in mCRC patients compared with healthy individuals. These results strongly suggest that the characterization of ccfDNA integrity hold great promise toward the development of a universal biomarker for the follow-up of mCRC patients. Furthermore, they support the importance of standardization of sample handling and processing in such analysis.

---

Fichiers liés : fonc-11-639675.pdf

---

Source